Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of SHR-3167 in Healthy Subjects and T2DM Patients
NCT05996380Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing SHR-3167 with SHR-3167 Placebo (2 arms). Primary endpoint: Number of Adverse Events at 92 days. Status: unknown.
02
Drugs
SHR-3167
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05996380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996380.